Mathias Klozenbuecher

ndependent Consultant: Innovation Management, Personalised Medicine, Genomics, digital therapy; Current customers include big Pharma and Startups in Logistics, Healthcare and Medical Device spaces.

Speedinvest is a leading European Platform Venture Capital fund. As Head of M&A and BD I am heading a group of 4 and am responsible for all portfolio related exit- and strategic partnership opportunities. - Completing all merger- and exit related activities. - Enabling strategic partnership opportunities for our portfolio companies through my network of corporate contacts - Turn around management of struggling portfolio companies - Decision support to all healthcare related investment opportunities

Palantir Technologies is a leader in big data integration and analytics. Leverage lead in the DACH region especially in the healthcare, pharma- and diagnostic environments. Customers include leading companies in the pharma-, automotive- and aviation industry. My responsibilities included: - New customer acquisition - Customer ‘upsell’ to deeply integrate our solution into the customer’s infrastructure - Help define a long-term growth- and leverage strategy for Palantir

Fabric is the leading software provider in the genomic analysis space translating it into clinical actionable results in rare diseases, oncology, cardiology, neurology, hereditary cancer and paediatrics. Fabric is paving the way for individualized medicine. Responsibilities include - Drive revenue - Transition the company into a clinical diagnostic company - Drive all 3rd party relationships - Negotiate, draft and execute strategic and sales partnerships - Define and implement new market entry strategies

Leading a team to plan and implement the growth strategy for the molecular diagnostic business of Siemens Healthcare. Responsibilities include: - Leading all M&A efforts in EUR 5B range - Implementing a short term revenue growth- and long term technology based strategy - Negotiating and executing supply and distribution partnerships, research collaborations and assay development programs - Implementing a sourcing strategy that reduces vendor dependency overall souring costs

Senior Director Project Management Siemens Healthcare Diagnostics, Office of the CEO, Tarrytown, NY Part of the diagnostic management team with EUR 5B in revenue. - Divestment projects in the EUR 350M range - Executing cross business unit strategy projects - Chief of staff of the Siemens Healthcare Diagnostics leadership team - Budget management for the EUR 5M divisional CEO cost center - Leading a complete product portfolio restructuring across 4 business units and over 1000 products

Project Manager for a division-wide global savings program; goal is to save EUR xxxM over 5 years. • Leading a 30+ cross functional team with members from finance, supply chain management, human resources, and external consultants to drive comprehensive savings initiatives in headcount, procurement, and productivity. • Defining strategies and leading workshops to facilitate meeting all project deliverables and milestones; • Preparing update presentations for Diagnostics CEO and CFO • Providing regular

Director of Business Development 2011 – 2012 Siemens Healthcare, Diagnostics, Molecular / Microbiology, Berkeley, CA Head of Business Development for Molecular and Microbiology, a business in the range of EUR 250M. Molecular diagnostics is a highly innovative field ranging from HIV testing to the more complex areas of genomic sequencing, companion diagnostics, mutational analysis, and treatment monitoring. • Evaluated new business opportunities worth up to EUR 10M. • Supported defining and realizing

Global Marketing Manager 2009 – 2011 Siemens Healthcare, Molecular Imaging, Hoffman Estates, IL Head of Global Marketing for SPECT and SPECT/CT imaging, used in a wide variety of clinical settings, from oncology to neurology to cardiology. Responsible for 7 products totaling sales of more than EUR 300M annually. • Helped to increase Siemens SPECT and SPECT/CT market share: global to 37% (from 32%), US to 49% (from 33%) and Germany to 83% (from 55%) • Launched product from beta testing to customer rout

Strategic Analyst 2008 – 2009 Siemens Healthcare, Erlangen, Strategy / Business Development, Erlangen, Germany Advisor to C-level management of Siemens Healthcare in acquisitions and divestments with exposure to all 9 healthcare business units • Evaluated healthcare wide business opportunities through market analysis, patent analysis, and competitive landscape analysis, including those in emerging healthcare markets • Advised on strategy of the sector

Staff Scientist, Department of Nuclear Medicine, Medical & Molecular 2006 – 2007 Pharmacology, David Geffen School of Medicine, UCLA - Los Angeles, CA Leader of a lung cancer research team and supported clinical trials. • Evaluated efficacy and toxicity of new drug candidates via in vivo microPET and microCT imaging • Executed in vitro studies and in vivo studies, and supported human clinical trials • Implemented new research modalities: microCT and microPET

Investment Manager 2003 – 2005 Inventages, Venture Capital Branch of Nestle, Lausanne, Switzerland • Investment manager and life sciences advisor to Inventages. • Performed independent evaluation of companies, their products, and clinical trial protocols. • Presented assessments and recommendations for investment decisions to the investment committee. • Recommended several investments; 3 still active today.

In vitro, in-vivo, lung cancer, imaging, kinase inhibitors